Vincristine加上Irinotecan能延長頑固依汶氏肉瘤年輕成人之末期生命

A combined regimen of vincristine plus irinotecan (i.e., VI regimen) was chosen during the search for an effective and affordable treatment for terminal Ewing sarcoma. We report our experience of prescribing four courses of VI for a 21-year-old man diagnosed with refractory Ewing sarcoma of the right sacrum with multiple metastases. In addition to dramatically reducing his tumor fever and systemic inflammation, his life was extended for five months longer than expected. Based on this case, we suggest considering using VI regimens in Ewing sarcoma not only for life-extending purposes but also as a first-line therapy for newly diagnosed high-risk patients.